Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions
Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQLNTH)
jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings topping analysts' expectations. Sales rose 10.5% year-on-year, fueled by high demand for its radiopharmaceutical products, including PYLARIFY, which crossed $1 billion in annual sales.
For 2025, the company set a bullish earnings forecast, well above consensus estimates. However, its full-year revenue outlook came in slightly below expectations, pointing to a more cautious growth path.
Overall, the quarter was decent, showcasing areas of strength in key product lines while highlighting some challenges, particularly in balancing revenue growth with increased spending on future initiatives.
Radiopharmaceutical company Lantheus Holdings (NASDAQLNTH) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.5% year on year to $391.1 million. On the other hand, the company’s full-year revenue guidance of $1.58 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.59 per share was 3% above analysts’ consensus estimates.
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQLNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2024.
LANTHEUS HOLDINGS INC was identified as a growth stock that isn't overvalued. NASDAQ:LNTH is excelling in various growth indicators while maintaining a solid financial footing.
Uncover the potential of LANTHEUS HOLDINGS INC, an undervalued stock. NASDAQ:LNTH maintains a strong financial position and offers an appealing valuation.
BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQLNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences.
BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQLNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024.
LANTHEUS HOLDINGS INC was identified as an affordable growth stock. NASDAQ:LNTH is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
LANTHEUS HOLDINGS INC has a stellar value proposition. NASDAQ:LNTH not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQLNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board’s Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus’ strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
Based on a technical and fundamental analysis of NASDAQ:LNTH we ask: Is LANTHEUS HOLDINGS INC (NASDAQLNTH) on the Verge of a Major Breakout as a Strong Growth Stock?
